Trial
NCT04169074
Immune Modulation by Abemaciclib in Head and Neck Squamous Cell Carcinoma (HNSCC). (AIM Trial)
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
University of Arizona
Collaborators
George Washington University
Condition
HNSCC
Intervention
Abemaciclib
Why stopped
Standard of care therapy for Stage III-IVA HNSCC updated in June to include neoadjuvant + adjuvant immunotherapy.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-05-22